Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 May;33(5):773–775. doi: 10.1128/aac.33.5.773

Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds.

J Seki 1, N Shimada 1, K Takahashi 1, T Takita 1, T Takeuchi 1, H Hoshino 1
PMCID: PMC172532  PMID: 2787618

Abstract

Oxetanocin is a novel nucleoside containing a 4-membered sugar, oxetanosyl-N-glycoside, and adenine. The effects of oxetanocin and related compounds on the infectivity of human immunodeficiency virus (HIV) were examined. They inhibited HIV infectivity in vitro. Allopurinol and mycophenolic acid produced additive anti-HIV effects when added with these compounds.

Full text

PDF
773

Images in this article

774Image
on p.774

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. De Clercq E. Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem. 1986 Sep;29(9):1561–1569. doi: 10.1021/jm00159a001. [DOI] [PubMed] [Google Scholar]
  3. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985 Aug 9;229(4713):563–566. doi: 10.1126/science.2992081. [DOI] [PubMed] [Google Scholar]
  4. Hoshino H., Shimizu N., Shimada N., Takita T., Takeuchi T. Inhibition of infectivity of human immunodeficiency virus by oxetanocin. J Antibiot (Tokyo) 1987 Jul;40(7):1077–1078. doi: 10.7164/antibiotics.40.1077. [DOI] [PubMed] [Google Scholar]
  5. Mitchell W. M., Montefiori D. C., Robinson W. E., Jr, Strayer D. R., Carter W. A. Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet. 1987 Apr 18;1(8538):890–892. doi: 10.1016/s0140-6736(87)92862-5. [DOI] [PubMed] [Google Scholar]
  6. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mitsuya H., Broder S. Strategies for antiviral therapy in AIDS. 1987 Feb 26-Mar 4Nature. 325(6107):773–778. doi: 10.1038/325773a0. [DOI] [PubMed] [Google Scholar]
  8. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nishiyama Y., Yamamoto N., Takahash K., Shimada N. Selective inhibition of human cytomegalovirus replication by a novel nucleoside, oxetanocin G. Antimicrob Agents Chemother. 1988 Jul;32(7):1053–1056. doi: 10.1128/aac.32.7.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  11. Shimada N., Hasegawa S., Harada T., Tomisawa T., Fujii A., Takita T. Oxetanocin, a novel nucleoside from bacteria. J Antibiot (Tokyo) 1986 Nov;39(11):1623–1625. doi: 10.7164/antibiotics.39.1623. [DOI] [PubMed] [Google Scholar]
  12. Shimada N., Hasegawa S., Saito S., Nishikiori T., Fujii A., Takita T. Derivatives of oxetanocin: oxetanocins H, X and G, and 2-aminooxetanocin A. J Antibiot (Tokyo) 1987 Dec;40(12):1788–1790. doi: 10.7164/antibiotics.40.1788. [DOI] [PubMed] [Google Scholar]
  13. Takeuchi Y., Inagaki M., Kobayashi N., Hoshino H. Isolation of human immunodeficiency virus from a Japanese hemophilia B patient with AIDS. Jpn J Cancer Res. 1987 Jan;78(1):11–15. [PubMed] [Google Scholar]
  14. Ueno R., Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet. 1987 Jun 13;1(8546):1379–1379. doi: 10.1016/s0140-6736(87)90681-7. [DOI] [PubMed] [Google Scholar]
  15. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES